Clinical analysis of liver injury in 164 patients with advanced non-small cell lung cancer after chemotherapy / 肿瘤研究与临床

ABSTRACT

Objective To analyze the changes and clinical significance of live function in advanced non-small cell lung cancer after chemotherapy.Methods The data of 164 patients histopathologically confirmed as advanced nonsmall cell lung cancer with complete medical history data from January 2007 to September 2010 were retrospectively analyzed.All the patients received chemotherapy by docetaxel or gemcitabine plus nedaplatin,regular liver function hematological monitoring and liver color ultrasound examination,which revealed the changes of liver function and liver morphology.Results Docetaxel or gemcitabine plus nedaplatin could induce liver function indexes abnormality in patients with advanced nonsmall cell lung cancer.The main symptoms were the rise of ALT,AST with different extent (ALT29 U/L vs 30 U/L,AST54 U/L vs 39 U/L,P ＜ 0.05),which were not related with the sex,age,tumor pathologic types and the clinical stages (P ＞ 0.05).Patients received chemotherapy by gemcitabine were inclined to experience liver function indexes abnormality (P ＜ 0.05).Patients with hepatic metastases and hepatitis B surface antigen positive before chemotherapy were inclined to experience liver function indexes abnormality (P ＜ 0.05).The ALP,γ-GT,TBL,ALB levels after treatment were almost the same as those before treatment (P ＞ 0.05).Conclusions Taking docetaxel or gemcitabine plus nedaplatin could induce liver function indexes abnormality in patients with advanced nonsmall cell lung cancer.Patients treated by chemotherapy complicated with hepatic metastases,hepatitis B surface antigen positive and treatment by gemcitabine were inclined to experience liver function indexes abnormality,which is value to research.